CellaVision, which develops and sells digital morphology products for the routine analysis of blood and other body fluids, has received its first Canadian order for the recently launched product CellaVision® DM1200. The order is for three analyzers, to be installed at small and mid-sized hospital sites throughout the health authority. Including the two CellaVision DM96 analyzers purchased earlier this year, the customer now has a total of five systems. The objective is to improve the quality of the manual differential results across hospitals of all sizes throughout the region. "Maintaining close customer relations and earning their trust are two of the most important factors in our ability to innovate and find solutions to our customer's problems, says Yvonne Mårtensson, CEO of CellaVision. "Our customer's decision to further invest in our digital morphology system confirms that we have succeeded in meeting the Canadian hematology market's requirements for improving the analytical flow, even for the smaller laboratory. It is strategically important for us to be entrusted to deliver a new product this soon after its introduction to the market, showing their confidence in doing business with CellaVision." The CellaVision® DM1200 replaces manual microscopy of blood samples and is aimed at hospital laboratories and independent commercial laboratories. Besides extra efficiency in the laboratory, the CellaVision automated technology permits proficiency and connectivity as the results of the analysis can be viewed from anywhere in the hospital, such as the physician's office. The distribution between different types of blood cells and their appearance are important criteria in diagnosis of a number of conditions such as infections and blood diseases. The CellaVision products are sold in Canada by the subsidiary CellaVision Canada Inc. Since obtaining its first Health Canada approval in 2007, the subsidiary has already sold over 30 instruments to Hospitals and Reference Laboratories in Ontario, British Columbia, Quebec, Saskatchewan, Nova Scotia and Newfoundland. For more information, please contact: Yvonne Mårtensson, CEO, CellaVision AB Phone: +46 708 33 77 82. E-mail: yvonne.martensson@cellavision.com About CellaVision CellaVision AB develops, markets, and sells market leading image analysis based systems for routine analysis of blood and other body fluids. The company has a core competence in development of software and hardware for automatic image analysis of cells and cell changes for applications in health and medical care. The company develops and markets systems for automatic differentials of white blood cells and red morphology, and software for education and quality assurance of differentials. The company's associates have expertise in advanced imaging analysis, artificial intelligence, and automated microscopy. The company headquarters are in Lund, Sweden. The company also has subsidiaries in Florida, USA, Toronto, Canada and Yokohama, Japan. For more information, visit www.cellavision.com. CellaVision's share is listed on First North Premier at the OMX Stockholm Stock Exchange. The company's Certified Advisor is Remium AB.